August 29, 2006
Product news from the 08/29/06 News Brief
The FDA yesterday approved several abbreviated new drug applications for generic versions of Bayer’s Cipro intravenous, a drug to treat certain bacterial infections. Ciprofloxacin Injection, is now indicated for the treatment of infections, including urinary tract infections, lower respiratory tract infections (including pneumonias in hospitalized patients, nosocomial pneumonia), bone and joint infections, complicated intraabdominal infections, skin and skin structure infections, and therapy of patients with fever and neutropenia.
The FDA has approved the use of UCB’s Keppra (levetiracetam) as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. Keppra is widely prescribed as an add-on therapy in the treatment of partial onset seizures in adults and children four years of age and older with epilepsy.